Cheng Ziyun, Mei Jianhui, Cao Suqi, Zhang Ran, Zhou Jiawei, Wang Yuwen
State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology and Optometry, Affiliated Eye Hospital, Wenzhou Medical University, Wenzhou, China.
Front Neurosci. 2021 Feb 19;15:624472. doi: 10.3389/fnins.2021.624472. eCollection 2021.
Atropine at a low concentration is considered a safe and effective treatment to mitigate myopia progression. However, the potential unwanted side effects of administering atropine at a low dose on visual functions other than best corrected visual acuity has not been investigated. In this study, we investigate the short-term (12,16, and 20 h) and long-term (1, 2, and 4 weeks) effects of 0.01% atropine (i.e., 0.1 mg/ml) on contrast sensitivity (CS) in patients with myopia.
Thirty adults (23.33 ± 2.93 years old) with myopia between -1.00 and -6.00 diopters (D), astigmatism of -1.50 D or less, and anisometropia of 1.00 D or less, participated in this prospective, masked, placebo-controlled, randomized study. The participants were randomly assigned to receive 0.01% atropine or polyvinyl alcohol eye drops once nightly to both eyes for four weeks. CS was measured binocularly at baseline and 12, 16, 20 h, 1, 2, and 4 weeks after the first use of the eye drops.
There was no statistically significant differences of CS found between atropine and placebo-controlled groups in both short-term and long-term. There was no statistically significant interaction effect found between the time and group.
We demonstrated no significant deleterious effect of 0.01% atropine on adult myopes' CS.
低浓度阿托品被认为是减轻近视进展的一种安全有效的治疗方法。然而，低剂量使用阿托品对除最佳矫正视力之外的视觉功能潜在的不良副作用尚未得到研究。在本研究中，我们调查了0.01%阿托品（即0.1毫克/毫升）对近视患者对比敏感度（CS）的短期（12、16和20小时）和长期（1、2和4周）影响。
30名年龄在23.33±2.93岁之间的近视成年人参与了这项前瞻性、双盲、安慰剂对照、随机研究，他们的近视度数在-1.00至-6.00屈光度（D）之间，散光在-1.50 D或以下，屈光参差在1.00 D或以下。参与者被随机分配每晚双眼滴注0.01%阿托品或聚乙烯醇眼药水，持续四周。在基线以及首次使用眼药水后的12、16、20小时、1、2和4周时双眼测量对比敏感度。
在短期和长期内，阿托品组和安慰剂对照组之间的对比敏感度均未发现有统计学意义的差异。时间和组之间未发现有统计学意义的交互作用。
我们证明了0.01%阿托品对成年近视患者的对比敏感度没有显著有害影响。
